Re Peter Mac.... I guess that's what I was getting at in my...

First 14 Last

Share
Profile

Follow
Shellbell

7,755 Posts.

3301

12/06/22

15:07

Post #: 61964853
Share

Originally posted by BigDaniel: ↑

Afternoon Shell.

If your talking about Peter MacCallum CAR-T programs external to OmniCar, not sure.

As wonderful as Peter MacCallum are, it's probably worth noting that the bulk of the stealth program was developed using Carina Biotech facilities.

So as for Peter MacCallum paying to license CellPryme, perhaps being such close collaborators with PTX there is a mutually beneficial arrangement in return for CellPryme use?

Perhaps Peter MacCallum give PTX concessions on use of facilities etc in return for licenses? I've no doubt that whilst Peter MacCallum is in pure pursuit of life changing advancements in cancer therapy, PTX would be paying for the use of Peter Mac facilities & either paying the entire wages of the 4x full-time technician or subsidising them.

Whilst nothing is free, the real blessing is Peter MacCallum want to partner with PTX. You can't buy your way in, you need genuine programs of merit with solid management I'd imagine if Peter MacCallum are to open their doors and resources.

As for the last posters question tòo, I couldn't imagine CellPryme requiring specific tools that we'd sell. It sounds more IP based, a simple technique adjustment during the manufacturing process that can easily be adapted by 3rd party in their current labs.

But don't worry, I think there will be very good coin for PTX shareholders in just the simple licensing of CellPryme. It's a fast growing therapy, only going to explode in years to come and I see it as been a very good earner for PTX. Might help subsidise our future registrational trials for OmniCar, PTX-100 & PTX-200 whilst keeping the share register tight.

Expand

Re Peter Mac.... I guess that's what I was getting at in my initial post... that we surely will have an agreement with Peter Mac for use of our platform since we already have a partnership of sorts with them. Perhaps they will simply tack on equivalent to a licensing fee to each of their customer's orders like a 50/50 arrangement.

The Rotea system is patented and owned by Thermo Fisher but likewise, we can incorporate it into our Cell Pryme platform whereby each of our customers pay a licensing fee to us and within that fee is a percentage factored in to pay TF for t he use of their equipment.

Not sure if I'm connecting the dots all that well, but think I can see a picture forming (albeit a bit fuzzy). Enough for me today... got other commitments to focus on this arvo. But PTX and Cell Pryme sure is intriguing.

PTX Price at posting: 19.0¢ Sentiment: Buy Disclosure: Held
4 Upvote

1 Great analysis

Reply

Top Stories

Your questions From the Floor: Investment experts respond...

GYG

Guzman Y Gomez shot up nearly 40% in first hour of trades. Can it last?

TM1

Shares up 196% on Terra's news of major reef discovery at Dante

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

BRX

Belararox delineates another porphyry in Argentina at Tambo South